Status:
COMPLETED
Financial Effects of a Tumor Disease - Development and Validation of a Patient Reported Outcome Measure in Germany
Lead Sponsor:
University Hospital Heidelberg
Collaborating Sponsors:
Chair of Methods in Empirical Social Research, Institute of Sociology, Technische Universität Dresden
Health Economics and Health Care Management, Bielefeld University
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to develop and to validate a standardised German-language instrument for measuring experienced financial effects of a cancer diagnosis and therapy in a cross-sectional bi-centre study....
Detailed Description
Methods and analysis: Phase 1: Construct definition and item generation Preliminary study: The preliminary study aims to identify dimensions, topics and risk factors that are relevant for the asses...
Eligibility Criteria
Inclusion
- Any type of historically or cytological confirmed solid cancer or haematological malignancy with an ECOG-Status \<2 and at least two month of cancer related therapy
- Patients are treated at the day care unit or ambulances of the NCT Heidelberg or oncological ward B100 at Jena University Hospital
Exclusion
- Patients younger than 18 years old
- Patients who refuse or withdraw from informed consent
- No sufficient level of German language
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT05319925
Start Date
June 1 2022
End Date
July 31 2023
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Center for Tumor Diseases, University Hospital Heidelberg
Heidelberg, Germany